These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6821814)

  • 1. Immune responses in patients with brain tumors. Factors such as anti-convulsants that may contribute to impaired cell-mediated immunity.
    Neuwelt EA; Kikuchi K; Hill S; Lipsky P; Frenkel EP
    Cancer; 1983 Jan; 51(2):248-55. PubMed ID: 6821814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect.
    McVicar DW; Davis DF; Merchant RE
    J Neurosurg; 1992 Feb; 76(2):251-60. PubMed ID: 1730954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired thymus-derived lymphocyte function in patients with malignant brain tumour.
    Menzies CB; Gunar M; Thomas DG; Behan PO
    Clin Neurol Neurosurg; 1980; 82(3):157-68. PubMed ID: 6260411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of immunosuppressive factors in brain-tumor cyst fluid.
    Kikuchi K; Neuwelt EA
    J Neurosurg; 1983 Nov; 59(5):790-9. PubMed ID: 6619930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.
    Brooks WH; Netsky MG; Normansell DE; Horwitz DA
    J Exp Med; 1972 Dec; 136(6):1631-47. PubMed ID: 4345108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro demonstration of cell-mediated immunity to human brain tumors.
    Levy NL; Mahaley MS; Day ED
    Cancer Res; 1972 Mar; 32(3):477-82. PubMed ID: 4334410
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas.
    Elliott LH; Brooks WH; Roszman TL
    J Neurosurg; 1987 Aug; 67(2):231-6. PubMed ID: 2885402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of lymphocyte-mediated cytotoxicity in patients with primary intracranial tumors.
    Levy NL
    J Immunol; 1978 Sep; 121(3):903-15. PubMed ID: 211167
    [No Abstract]   [Full Text] [Related]  

  • 9. General immunocompetence of rats bearing avian sarcoma virus-induced intracranial tumors.
    Roszman TL; Brooks WH; Markesbery WR; Bigner DD
    Cancer Res; 1978 Jan; 38(1):74-7. PubMed ID: 201377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capacity of sera from patients with primary intracranial tumors to support mitogen stimulation of blood lymphocytes. Correlation to histological tumor type.
    Blomgren H; Blom U; Ullén H
    Anticancer Res; 1985; 5(4):349-54. PubMed ID: 4037733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble membrane antigens of brain tumors. I. Controlled testing for cell-mediated immune responses in a long surviving glioblastoma multiforme patient.
    Hitchcock MH; Hollinshead AC; Chretien P; Rizzoli HV
    Cancer; 1977 Aug; 40(2):660-6. PubMed ID: 196738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells.
    Wood GW; Morantz RA
    J Neurooncol; 1983; 1(2):87-94. PubMed ID: 6236289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunological monitoring of brain tumors--prognosis based on T-lymphocyte subpopulations and skin testing for delayed hypersensitivity].
    Yokoyama H; Nakadai M; Asou Y; Maeda T; Ogashiwa M; Takeuchi K
    No To Shinkei; 1985 Feb; 37(2):193-9. PubMed ID: 3873952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human intracranial tumors: effect of autologous serum addition on leucocyte migration inhibition.
    Böker DK
    Acta Neurochir (Wien); 1982; 65(3-4):227-37. PubMed ID: 7180599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A correlation between serum immunosuppressive acidic protein and altered immunocompetence in patients with brain tumours.
    Kikuchi K; Gotoh H; Kowada M
    Acta Neurochir (Wien); 1990; 103(1-2):52-61. PubMed ID: 2360468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitogen stimulation of blood lymphocytes from patients with primary intracranial tumors. Correlation to histological tumor type.
    Blom U; Blomgren H; Ullén H; Collins P; Von Holst H
    Anticancer Res; 1985; 5(4):343-8. PubMed ID: 4037732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas.
    Gately MK; Glaser M; Dick SJ; Mettetal RW; Kornblith PL
    J Natl Cancer Inst; 1982 Dec; 69(6):1245-54. PubMed ID: 6183477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lymphocyte subpopulations and their functional activity in patients with brain tumors].
    Rudenko VA; Lisianyĭ NI; Radzievskiĭ AA
    Vrach Delo; 1990 Sep; (9):91-4. PubMed ID: 2284786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cell-mediated immunity in patients with brain tumors.
    Young HF; Sakalas R; Kaplan AM
    Surg Neurol; 1976 Jan; 5(1):19-23. PubMed ID: 1265620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors.
    Brooks WH; Roszman TL; Rogers AS
    Cancer; 1976 Apr; 37(4):1869-73. PubMed ID: 769940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.